This site is intended for healthcare professionals

BioMarin provides highlights of 4 Years of clinical data from ongoing phase 1/II study of valoctocogene roxaparvovec gene therapy for severe hemophilia A.

Read time: 1 mins
Last updated:1st Jun 2020
Published:2nd Jun 2020
Condition: Haemophilia A
Type: drug
Register free for full access to